Channel Therapeutics Corporation (CHRO) Research

Channel Therapeutics Corporation operates as a clinical-stage biotechnology company, committed to the entire process of identifying, advancing, and bringing to market novel therapies aimed at reducing pain. Its research strategy centers on precisely inhibiting the NaV1.7 sodium ion-channel, in addition to other related receptors within the broader NaV family. The firm's flagship investigational drug, CC8464, is currently undergoing Phase 2a clinical evaluation. This compound is being explored for its potential efficacy in treating erythromelalgia and diverse forms of neuropathic pain. Founded in 2002, this New Jersey-based entity maintains its corporate headquarters in Freehold.

Market snapshot

Symbol
CHRO
Price
$1.35
Day change
+7.14%
Market cap
$8.9M
P/E ratio
-0.09x
52-week range
1.2301-54.29
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Apexigen, Inc. (APGN)
  • Biora Therapeutics, Inc. (BIOR)
  • CervoMed Inc. (CRVO)
  • COSCIENS Biopharma Inc. (CSCI)
  • IMV Inc. (IMVIF)
  • ObsEva S.A. (OBSV)
  • Omega Therapeutics, Inc. (OMGA)
  • TNF Pharmaceuticals, Inc. (TNFA)

Recent insider activity

  • Simmons Chia-Lin — A-Award (25000 shares) on 2025-04-11
  • Francis Knuettel II — A-Award (53988 shares) on 2025-04-11
  • Davis Todd C — A-Award (49605 shares) on 2024-11-13
  • Malamut Richard — A-Award (24533 shares) on 2024-11-13
  • Friedberg Ezra M — A-Award (24533 shares) on 2024-11-13

Open Channel Therapeutics Corporation (CHRO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.